DOA
HZNP

D'Orazio & Associates’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

D'Orazio & Associates’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-11
Closed -$1K – 772
2021
Q3 		$1K Buy
+11
New +$1.14K ﹤0.01% 761

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

D'Orazio & Associates's HZNP Position: Q4 2021 in Review

D'Orazio & Associates sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2021, closing a stake of 11 shares — an estimated $1K sold.

D'Orazio & Associates first reported a position in HZNP in Q3 2021 and held it in 1 quarter. The position peaked at $1K in Q3 2021. 611 funds tracked by Wall St. Rank hold HZNP as of Q4 2021.

  • D'Orazio & Associates reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2021 after selling out during the quarter.
  • D'Orazio & Associates sold 11 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2021, an estimated $1K.
  • D'Orazio & Associates first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2021 and held it in 1 quarter.
  • D'Orazio & Associates's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $1K in Q3 2021.
  • 611 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2021.

Based on D'Orazio & Associates's 13F filing for Q4 2021, filed 7 Feb 2022.